# OnCo record point-biopharma (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/point-biopharma/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "point-biopharma" ;
  schema:name "POINT Biopharma"@en ;
  schema:description "POINT Biopharma developed radioactive medicines that home in on prostate cancer and neuroendocrine tumours, and built a large manufacturing campus in Indianapolis. Eli Lilly bought the company at the end of 2023."@en ;
  schema:url <https://onco.cc/companies/point-biopharma/>, <https://www.lilly.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.lilly.com/>, <https://www.sec.gov/Archives/edgar/data/1811764/000110465923106146/tm2327397d1_8k.htm>, <https://www.sec.gov/Archives/edgar/data/1811764/000110465923106146/tm2327397d1_ex99-4.htm>, <https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/d594310d8k.htm> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/neuroendocrine/> ;
  onco:sections <https://onco.cc/fronts/radiopharma/> ;
  onco:technologies <https://onco.cc/technologies/radioligand-therapy/> ;
  onco:targets <https://onco.cc/targets/psma/>, <https://onco.cc/targets/sstr2/> .